Remus Pharmaceuticals Ltd Stock Price Today (NSE: REMUS)
Fundamental Score
Remus Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Remus Pharmaceuticals Ltd share price today is ₹951.15, down 3.81% on NSE/BSE as of 22 September 2026. Remus Pharmaceuticals Ltd (REMUS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹871.48 (Cr). The 52-week high for REMUS share price is ₹1007.00 and the 52-week low is ₹600.00. At a P/E ratio of 23.56x, REMUS is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 12.19% and a debt-to-equity ratio of 0.08.
Remus Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Remus Pharmaceuticals Ltd share price chart: 6.98% return over the past month. 52-week high ₹1007.00, 52-week low ₹600.00.
Remus Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1002.00 | ₹1002.00 | ₹942.00 | ₹951.15 | 6.10K (Cr) | |
| ₹971.00 | ₹994.80 | ₹966.15 | ₹988.80 | 2.90K (Cr) | |
| ₹998.00 | ₹1007.00 | ₹977.00 | ₹979.05 | 8.50K (Cr) | |
| ₹883.00 | ₹986.00 | ₹883.00 | ₹972.10 | 48.10K (Cr) | |
| ₹870.00 | ₹875.00 | ₹835.10 | ₹866.35 | 7.40K (Cr) | |
| ₹867.45 | ₹891.80 | ₹854.00 | ₹884.80 | 6.50K (Cr) | |
| ₹880.10 | ₹892.95 | ₹870.00 | ₹880.00 | 5.90K (Cr) | |
| ₹924.00 | ₹924.00 | ₹880.00 | ₹893.05 | 3.80K (Cr) | |
| ₹894.50 | ₹932.00 | ₹894.50 | ₹928.85 | 11.70K (Cr) | |
| ₹896.35 | ₹916.60 | ₹884.85 | ₹912.75 | 9.50K (Cr) |
Remus Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹900.00 | ₹1007.00 | ₹835.10 | ₹951.15 | +5.68% | |
| ₹725.00 | ₹987.50 | ₹725.00 | ₹899.45 | +24.06% | |
| ₹761.00 | ₹790.00 | ₹705.00 | ₹720.00 | -5.39% | |
| ₹723.00 | ₹729.70 | ₹715.00 | ₹715.00 | -1.11% | |
| ₹710.00 | ₹937.00 | ₹700.45 | ₹712.55 | +0.36% | |
| ₹648.00 | ₹710.00 | ₹600.00 | ₹699.80 | +7.99% | |
| ₹620.00 | ₹679.00 | ₹601.00 | ₹612.75 | -1.17% | |
| ₹680.00 | ₹719.00 | ₹639.05 | ₹711.40 | +4.62% | |
| ₹770.00 | ₹847.00 | ₹631.05 | ₹646.00 | -16.10% | |
| ₹706.00 | ₹760.00 | ₹611.05 | ₹702.20 | -0.54% | |
| ₹760.90 | ₹830.00 | ₹698.00 | ₹734.45 | -3.48% | |
| ₹740.00 | ₹754.00 | ₹636.10 | ₹655.70 | -11.39% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Remus Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Remus Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of REMUS across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Excellent ROCE Performance (16.83%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 23.56 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (21.74%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (30.39%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.08)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (41.24x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (70.95%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Limited Institutional Interest (FII+DII: 6.11%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Remus Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Remus Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
45.1/100 | ₹951.15₹951 | ₹871.48₹871.48 | 23.56Average 23.6 Average | 12.19%Average 12.19% Average | 16.83%Good 16.83% Good | 0.08Excellent 0.1 Excellent | — — | — — | 0.14% | |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1861.00₹1861 | ₹446509.73₹446509.73 | 36.92Average 36.9 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9438.50₹9439 | ₹250120.25₹250120.25 | 85.64Average 85.6 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1117.80₹1118 | ₹111556.44₹111556.44 | 24.91Average 24.9 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1373.30₹1373 | ₹110942.04₹110942.04 | 32.90Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1945.00₹1945 | ₹105078.63₹105078.63 | 96.00Average 96.0 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1668.40₹1668 | ₹95999.74₹95999.74 | 26.07Average 26.1 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1143.00₹1143 | ₹95440.50₹95440.50 | 29.54Average 29.5 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2077.80₹2078 | ₹95007.40₹95007.40 | 17.17Average 17.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2238.40₹2238 | ₹92445.92₹92445.92 | 45.23Average 45.2 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price446509.73 Cr
- Divi's Laboratories Limited share price250120.25 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price111556.44 Cr
- Cipla Limited share price110942.04 Cr
Remus Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for REMUS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
30.39%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
21.74%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Remus Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for REMUS — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Remus Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Remus Pharmaceuticals Ltd (REMUS) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Remus Pharmaceuticals Ltd
About REMUS (Remus Pharmaceuticals Ltd)
Remus Pharmaceuticals Ltd (REMUS) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a... current market capitalisation of ₹871.48 (Cr). Remus Pharmaceuticals Ltd has delivered a Return on Equity (ROE) of 12.19% and a ROCE of 16.83%. The debt-to-equity ratio stands at 0.08, reflecting the company's capital structure. Investors tracking REMUS share price can monitor key metrics including P/E ratio, promoter holding of 70.95%, and quarterly earnings growth.
Company Details
REMUS Share Price: Frequently Asked Questions
What is the current share price of Remus Pharmaceuticals Ltd?
Remus Pharmaceuticals Ltd (REMUS) trades at ₹951.15 on NSE. Market cap ₹871.48 (Cr). Educational data only.
What is the P/E ratio of Remus Pharmaceuticals Ltd?
Remus Pharmaceuticals Ltd has a P/E of 23.56x vs industry average 34.89x.
What is the Bull Run score for Remus Pharmaceuticals Ltd?
Remus Pharmaceuticals Ltd has a Bull Run score of 45.1/100 based on 25+ financial parameters.
Does Remus Pharmaceuticals Ltd pay dividends?
Remus Pharmaceuticals Ltd has a dividend yield of 0.14%. Past dividends don't guarantee future payments.
What is the ROE of Remus Pharmaceuticals Ltd?
Remus Pharmaceuticals Ltd has ROE of 12.19%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Remus Pharmaceuticals Ltd?
Remus Pharmaceuticals Ltd has debt-to-equity of 0.08.
Is Remus Pharmaceuticals Ltd a good investment?
Bull Run gives Remus Pharmaceuticals Ltd a score of 45.1/100. This is not investment advice — consult a SEBI-registered advisor.